Evaluate for Biotech

Built specifically for biotechs with ambition

Evaluate provides biotechs with curated products to substantiate the value of a lead asset at an early stage. With Evaluate's breadth of data coverage, biotechs can uncover opportunities at an earlier stage and stand out from the competition.

Stand Out

Read and download our analysis into biotech funding in H1 2022

IPOs in Q2 2022

2022 has seen the IPO window slam shut

Not since 2012 has the biotech sector seen such a dismal period for initial public offerings. A slow Q1 of 2022 was followed by an almost-complete standstill in Q2 with a total of just 13 drug developers getting away in the first half of the year. With the IPO window shut, biotechs need to look for different avenues to secure funding and growth.

Data and Features Available to Biotech

What Evaluate can do for biotechs

Evaluate provides enterprise-level access to a number of leading features from across the Evaluate portfolio — including Evaluate Pharma, Omnium Risk and Evaluate Epi — for individuals multi-tasking under resource constraints.

Improve your ability to substantiate the value of a lead asset, stand out against competition and secure the desired commercial exit.

Small Needs An Advantage
Evaluate BiOptica
Evaluate Pharma, Omnium Risk and Evaluate Epi features available

Market Explorer Dashboard

WATCH THE 1 MINUTE DEMO. An accessible, interactive interface offering insights about the market, market value, and underlying dynamics influencing market valuations. Includes a total of $1.1tn worldwide sales by indication calculated to 2026, sales by technology and mechanism of action, CAGRs, market leaders, product counts, and top 10 products by current indication phase.

Portfolio Analyzer Dashboard

WATCH THE 1 MINUTE DEMO. An interactive comparison matrix to benchmark company porfolios and assess their strengths and weaknesses in order to quickly evaluate potential companies of interest. Includes a total of $1.1tn worldwide sales by indication calculated to 2026, CAGRs, and portfolio growth analysis and rank by company, technology, and indication levels 1-3.

Competitor Analyzer Dashboard

WATCH THE 1 MINUTE DEMO. Quickly assess the clinical pipeline landscape across an interactive interface, to compare company sales, pipelines and pipeline designations. Includes a total of $1.1tn worldwide sales by indication calculated to 2026, CAGRs, pipeline composition count by indication, and top 10 rankings of companies, companies' active products, and product indication sales over time.


Track thousands of deals by company, product, therapy area, compound phase, deal value and much more. Evaluate maintains historic deal data as well as venture financing and IPO information across pharmaceutical and biotech companies.

Clinical Trials

Focus on the trials impacting the commercial landscape with a commercial trial filter across 350,000+ clinical trials, 216+ countries and 314,000 trial investigators mapped to 7,500+ pharma/biotech companies and 820+ indications.

Product-Specific Success Rates

Predicts which in-house or competitor drugs are most likely to reach the market, so you can compare risk levels across products or indications. Includes product-specific probability of technical and regulatory success (PTRS), fully transparent risk audits and success rate benchmarks.

Epidemiology Data

Access a highly granular epidemiology data for 220+ indications and 9,000+ sub-populations across 27 core markets, including the USA, Europe, Japan and the BRICs. Interrogate the data by key demographic segments and indications for more robust analysis and forecasting of patient populations.

Consensus Forecasts & Archived Forecasts

Our deep industry knowledge and analytical expertise allow us to create the highest quality consensus forecasts and give our clients solid benchmarks for their strategic decisions.

Unique to the market as the largest back catalogue of consensus drug forecasts, Evaluate's Archived Forecasts cover 485,000+ forecasts across 11,000+ drugs, dated back to January 2003. Analyse drug progression across monthly archives and use it in coordination with Event Analyzer to understand the news events that led to consensus forecast changes.

NPV Analyzer

A standardised and systematic approach to calculating a product's Net Present Value (NPV), based on discounted cash flow models to 2040 for over 6,000 products. Edit assumptions to create custom models tailored to specific requirements: annual and peak sales, patent expiry dates, cost of capital, tax rates.

R&D Costs & Development Timelines

Provides the industry’s first comprehensive clinical trial costing model, applying real-world data to over 50,000 trials, so you can better assess likely costs across the development cycle. Includes estimated, product-level trial costs for past and current clinical trials, future R&D cost predictions and industry benchmarks by indication.

Predict when key development milestones will occur. Track progress against competitors or highlight products with first-in-class potential. Includes time-in-phase, launch date and market entry order predictions, as well as recruitment timeline benchmarks.


Analyse key patent expiration dates and the worldwide and US sales at risk.

Company Financials

Includes financial metrics by company: aggregated profit and loss to 2026, CAGRs ranked, comparison by reported income.

Event Analyzer & Calendar of Events

Event Analyzer is a daily and weekly round-up of the stock price winners and losers and the underlying news events impacting the pharmaceutical and biotech company share prices and valuations.

Calendar of Events offers daily insights and email alerts with insight into future critical events related to a product's life cycle and provides company guidance around development and regulatory timelines.

Report Editor Functionality

Edit any pre-built reports as well as create individual, custom reports from scratch. Add, remove or reorder components so that information is tailored to your query.

Watch: Market Explorer Dashboard

Our Market Explorer dashboard empowers you to conduct fast, repetitive sizing to keep up with your target market's fluidity.

Its accessible interface offers insights about the market, market value, and the underlying dynamics influencing market valuations. It also includes: worldwide indication sales by year, compound annual growth rates, company share of indication, market leaders and fastest growing companies.

Watch: Portfolio Analyzer Dashboard

The Portfolio Analyzer dashboard provides deeper insight into company portfolios, enabling you to identify potential partners based on aligned strategic goals. It also includes: product and company counts, portfolio growth by indication, analyse portfolios by company, technology and 3 indication levels.

Watch: Competitor Analyzer Dashboard

Our Competitor Analyzer dashboard gives you the power to examine competitors' potential market share, sales and development portfolios. It also includes: product by indication count, pipeline composition count by indication, top 10 companies' worldwide product indication sales.

To explore Evaluate further, request a demo

Evaluate gives us more confidence in our decisions – I’d be loath to go to our leadership team with therapeutic area or target recommendations without the information it provides us.

Nathan Dowden, Former Senior VP of Corporate Development, Rubius Therapeutics

Evaluate gives us confidence in our due diligence around the market size and value, which makes us a much more powerful negotiator when we bring a deal to the table.

Thaminda Ramanayake, Former Director, Business Development, BioMarin Pharmaceutical